Treatment of Wilson Disease With Ammonium Tetrathiomolybdate - Wikidata - awgldk - TriplyDB

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

http://www.wikidata.org/entity/Q29396107

about

Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease Fine motor skills disorders in the course of Wilson's disease.A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer Impairment of interrelated iron- and copper homeostatic mechanisms in brain contributes to the pathogenesis of neurodegenerative disorders.Wilson's disease: A review of what we have learned.Novel therapeutic approaches to the treatment of Wilson's disease.Advance in the pathogenesis and treatment of Wilson disease.Methanobactin and the Link between Copper and Bacterial Methane Oxidation Current Drug Managements of Wilson's Disease: From West to East.Copper in Alzheimer's disease: too much or too little?Update on the clinical management of Wilson's disease.Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring.Wilson's disease: update on integrated Chinese and Western medicine.Treatment of Wilson's disease motor complications with deep brain stimulation.Clinical considerations for an effective medical therapy in Wilson's disease.Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy.Low-glucose conditions of tumor microenvironment enhance cytotoxicity of tetrathiomolybdate to neuroblastoma cells.A study of clinical, MRI and multimodality evoked potentials in neurologic Wilson disease.Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.Tetrathiomolybdate is partially protective against hyperglycemia in rodent models of diabetes.Insights into the management of Wilson's disease.Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.Tetrathiomolybdate Treatment Leads to the Suppression of Inflammatory Responses through the TRAF6/NFκB Pathway in LPS-Stimulated BV-2 Microglia.Ionic Homeostasis Maintenance in ALS: Focus on New Therapeutic Targets

P2860

Q26748245-4A9EE17F-73D1-462B-B910-608571B9FF34 Q26773881-9CD0A1E8-63F9-401E-9994-BA4CBCD53C74 Q33612977-90D10C37-39D3-49E5-9545-1390BAAD9615 Q34134308-7680CE65-D37F-4E24-9183-D5383447E624 Q34224045-89CEC6A2-0172-4F16-BD2D-0486C3A9332A Q34291420-28068EA2-18B4-45CA-AD6D-83F74622A7C8 Q36275015-FA15B9D7-A887-4221-88C0-EB8C9C246DAA Q36369817-AF96AEC1-0AF9-436A-BE13-C37AED8AF734 Q36382586-CFF2029F-9278-4846-8A8B-4E444562CC49 Q36478429-7FB9ACE6-A60F-445F-AC56-0B5E8527BC87 Q36902463-AAC2207C-8380-49B3-A55B-C76D591CF1D5 Q36925896-21F72903-4F09-4377-8CFD-6011D1FAC6E4 Q37464172-471FF81E-EEE7-493F-977E-2DA0C21FCEF3 Q37594596-8AD18FC4-9BAE-4F64-BF18-7E1A40E91E27 Q37686235-9671F380-6F67-4D72-AB81-4C3889CF79DF Q37956131-FBB67C47-A672-4D28-9A66-B28D588AEA1C Q38011659-74715BE2-6BCD-41E7-9E77-B5734D904D02 Q38189115-10BC10FF-C981-4A82-BECE-454365AA0425 Q38206268-173757EE-2136-465B-9CA7-BFB4AE219E62 Q38979671-1064A1E1-91C0-4A89-8C00-F7B2600C1A20 Q39125256-EAE7ACAB-A1BB-48DA-A82A-5DDD3D720E99 Q42511173-48BEB5A4-7A1B-4D5C-80F0-3F92588F242E Q46078181-E9DCD21F-8859-484E-9B12-1B1AED276049 Q46595587-89E97877-04B4-40DA-B1DA-296AB756E8F3 Q47105991-700593BE-DA74-4D68-86D3-47ABACAA0902 Q47843934-223B73F6-DCAD-4F53-8DAD-580892C00F2D Q51763391-B4DD93F2-2F70-41A7-A7AF-2B4950CF5E37 Q57170405-6A68EFCB-CEED-426E-87CF-50A02F74227F

P2860

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

http://www.wikidata.org/entity/Q29396107

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@ast

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@en

type

label

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@ast

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@en

prefLabel

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@ast

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@en

P1433

Q29396107-9E8438CC-AFF0-4E3F-817E-53A1734B8980

P1476

Q29396107-BCF51D8F-0822-4CA3-B75B-8C8778510908

P2093

Q29396107-1471B97C-9AF8-470A-8637-101B05591F3C

Q29396107-23F68973-FEBF-4021-A998-AFFEDE88D375

Q29396107-8E319589-212D-4E32-98EB-2D9EC6C4D68A

Q29396107-91C3321A-8DBB-493B-9A9C-F076527A6DCE

Q29396107-A6FE8C1F-DDCC-4065-85B3-47E771E65F75

Q29396107-B749A115-986B-4688-AC61-97020E69343D

Q29396107-C457B2E9-CDDC-480F-93AD-D7A7FCA400FB

Q29396107-EF053545-3A23-4745-B3F5-20F8129F6FF7

P304

Q29396107-A5D405FC-02BD-4B5F-AFD2-5DB5DE4531F5

P31

Q29396107-6AE5F1B5-FCD9-4201-AEF9-082119DFE9DC

P3181

Q29396107-2C46E15A-AC25-4F0C-9374-7802EA1DEB38

P356

Q29396107-057CF125-36A0-4153-922A-B7D9EE56D390

P433

Q29396107-8DFC5B06-B6F1-436E-A771-C4A56660F31F

P478

Q29396107-BEFDC3F2-1934-47CD-9A85-C4C2C6A97C0E

P577

Q29396107-4C668C17-2290-47AF-83B5-8F72D576A497

P698

Q29396107-1EE4E882-77DC-47B8-B42C-41E9B4374941

P3181

P356

ARCHNEUR.60.3.379

P1433

P1476

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

@en

P2093

Fred Askari

http://www.w3.org/2001/XMLSchema#string

George J. Brewer

http://www.w3.org/2001/XMLSchema#string

John K. Fink

http://www.w3.org/2001/XMLSchema#string

Julia Sitterly

http://www.w3.org/2001/XMLSchema#string

Karen J. Kluin

http://www.w3.org/2001/XMLSchema#string

Martha Carlson

http://www.w3.org/2001/XMLSchema#string

Peter Hedera

http://www.w3.org/2001/XMLSchema#string

Robert B. Dick

http://www.w3.org/2001/XMLSchema#string

P304

379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2013231

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/ARCHNEUR.60.3.379

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12633149

http://www.w3.org/2001/XMLSchema#string